Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can a tablet or VR headset help cancer patients recover at home?

NCT ID NCT07390071

First seen Feb 05, 2026 · Last updated Jun 23, 2026 · Updated 22 times

Summary

This study tests a home-based telerehabilitation program for adults with lymphoma or myeloma who have received CAR-T cell therapy. Participants use a tablet or VR headset, along with a pulse oximeter and Fitbit, to follow personalized exercise and nutrition plans. The goal is to see if this approach is feasible and improves quality of life and recovery. The study enrolls 40 people and focuses on usability and adherence.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Huntsman Cancer Institute at University of Utah

    RECRUITING

    Salt Lake City, Utah, 84112, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Home Automated Telemanagement (HAT) patient unit (device including tablet or VR headset, pulse oximeter, and Fitbit)

What this could lead to

If successful, this could show that a home-based rehab program improves quality of life and recovery for blood cancer patients after CAR-T therapy.

What could go wrong

This is a small pilot study with only 40 participants, so results may not apply to everyone. The program's success depends on patient adherence and technology usability.

Conditions

The condition(s) this trial relates to.

cytokine release syndrome lymphoma plasma cell myeloma plasma cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.